Diamyd Medical presents clinical data at the BIO CEO & Investor Conference 2009 in New York

Diamyd Medical announces today that Elisabeth Lindner, President and Chief Executive Officer of the company, has been invited to speak at the BIO CEO & Investor Conference in New York on February 9. The presentation will take place at 2.45 pm at the Waldorf Astoria.

Diamyd Medical develops pharmaceuticals for treatment of autoimmune diabetes. The worldwide cost for treatment of diabetes and its complications exceeds USD 230 billion per year (International Diabetes Federation). Diamyd Medical’s most advanced project is the diabetes vaccine Diamyd® for treatment of type 1 diabetes. The vaccine has been shown to have the potential to stop or delay the break-down of insulin-producing beta cells in recent-onset type 1 diabetes, as reported in the New England Journal of Medicine, October 2008. It has been shown in the “Diabetes Control and Complications Trial” (NIH/NIDDK 1983-1993) that a residual insulin-producing capacity reduces the risk for diabetes complications by more than 60 percent in type 1 diabetes. The Diamyd® diabetes vaccine is currently in large scale Phase III programs in Europe and the US. The company plans to submit its New Drug Application in 2011. A hypothesis is that by first stopping the autoimmune attack in type 1 diabetes with the Diamyd® diabetes vaccine, and then stimulating regeneration of beta cells, the insulin-producing capacity could be restored. The company has recently disclosed a planned NIH/NIDDK study with Diamyd® in combination with beta cell stimulating agents aimed at preserving or restoring the insulin-producing capacity in type 1 diabetes patients. Previously, Diamyd Medical has established similar partnerships with key opinion leaders in the Type 1 Diabetes TrialNet network in the US, which is now initiating a study with Diamyd® in 126 patients. Diamyd Medical also works with two of the most prominent type 1 diabetes research groups in the Nordic countries with a focus on preventing the disease. In a proprietary gene therapy program, Diamyd Medical is currently investigating its Nerve Targeting Drug Delivery System (NTDDS) in a Phase I clinical trial with delivery of enkephalin to patients with chronic pain.

Tags: